Paul Mampilly is out with a teaser pitch for his Profits Unlimited newsletter from Banyan Hill, which is the entry-level ($97/yr) stock picking letter for that publisher (which used to be called the Sovereign Society). I first covered this for the Irregulars about a month ago, but we’re still getting a lot of questions so […]
I’ve gotten quite a few questions about this spiel, which was for a recommendation that Mampilly was supposed to release yesterday (and presumably did) to his Extreme Fortunes subscribers, so I’m taking a look… despite the fact that I’m a little sick of writing about bitcoin. Extreme Fortunes is the “high end” newsletter Mampilly writes […]
Fridays are the day I write for you, my dear Irregular friend, so this time you’re getting a teaser solution that I’ve been inspired to write about today, plus a few updates on my Real Money Portfolio stocks. First, those (pretty minor) updates… One of the worst-performing stocks I own over the past year or […]
My eyes lit up when I saw the latest ad from Paul Mampilly for his Profits Unlimited newsletter — more geothermal! Woohoo! Even the ad looked familiar — we saw quite a few of those ‘heat map’ images of the US five or ten years ago when geothermal stocks “heated up,” so it gave me […]
Paul Mampilly is out with a new promo for his Extreme Fortunes newsletter, making this absurd promise: “Anyone who joins my research service Extreme Fortunes, and invests $10,000 following my recommendations, will have the chance to earn a profit of $100,000… in the next year.” So before we begin, let’s throw away that possibility. You’re […]
“Upgrade” newsletter from Paul Mampilly at Banyan Hill, focuses on targeting 1,000% gains “on every single trade” in small cap stocks that are “disruptive.”
Today, for your holiday reading pleasure, we’re re-sharing a teaser solution that’s still being asked about (and apparently still being heavily promoted by the Sovereign Society folks). The original solution to this teaser appeared in a Friday File commentary, so some of you may not have seen it. I’ve excerpted most of the teaser solution […]
A few things to blather on about for you today — a teaser, a new mutual fund I’ve been following that has some appeal (and some of my money now), and some quick updates on my portfolio. First, though, I want to call attention to our discussions here at Stock Gumshoe. Most readers will never […]
Relatively new letter in 2016, priced as an entry level letter, with goal to “get in on the ground floor in innovative companies that are just about to see explosive growth.” Mampilly previously worked on letters for Palm Beach, Stansberry and Agora Financial over the past four years. Banyan Hill (the publisher) used to be […]
I’ve got a few stocks to mention in the medical space this week — one to update that’s in my portfolio, one to confirm as a teaser pick (since folks keep asking) after several Gumshoe readers discussed it last week, and one to note as a teaser idea that’s being pushed pretty heavily (though the […]
How about something on Stansberry’s latest – “Pinpoint Surgery” stock?
This is a quickie for you, I came across it and don’t want to write up a full look at the company but I thought some of you would like the teaser solution. The ad’s from Agora Financial’s FDA Trader, which has been touting this “magic calendar” idea of investing in stocks around (mostly) PDUFA […]
That’s right, the end of obesity. That’s what’s being touted by the new letter that as far as I can tell was just launched moments ago by Agora, which they’re calling FDA Trader and for which they apparently hired away Paul Mampilly from the Palm Beach Letter (OK, they didn’t really “hire him away” — […]
Biotech trading advisory/newsletter.
It’s been a few months since I last wrote about a teaser pitch from the Palm Beach Letter, the “entry level” letter from Common Sense Investing that was started in the last year or so by ex-Stansberry pundit Tom Dyson and marketing guru Michael Masterson/Mark Ford. (Yes, I say “entry level” even though this is […]